Quick Facts

• Primary Therapeutic Area: Management of Type 2 Diabetes Mellitus.
• Goal: Used in adults to help with the regulation of blood glucose levels.
• Context: Intended as an adjunct to prescribed diet and regular physical activity.

---

Glicron is a prescription treatment used for the long-term management of Type 2 Diabetes Mellitus in adults. Its primary function is to support the body's processes involved in glucose control, which helps mitigate high blood sugar (hyperglycemia) that may occur with this condition.

This medication is a component of a comprehensive treatment plan that must also include lifestyle modifications, such as a proper diet and exercise regimen. By assisting in the regulation of blood sugar, Glicron contributes to the patient's overall metabolic balance and helps reduce the potential for related health issues over time. Patients should consult their healthcare professional for a complete understanding of their therapeutic options and the specific role of this medication.

Regulatory References

1. NIH MedlinePlus guidance

Eligibility Map: Who Can and Cannot Use Glicron (Gliclazide) — Official Regulatory Information

Category	Official Regulatory Status and Constraint
Populations for whom use is allowed	Adults with Type 2 Diabetes Mellitus when diet and exercise alone are insufficient.
Populations for whom use is not recommended	Children and adolescents (under 18 years of age), as safety and efficacy have not been established.
Populations for whom use is contraindicated	Patients with Type 1 Diabetes Mellitus, diabetic keto-acidosis, diabetic pre-coma/coma, or hypersensitivity to Gliclazide, other sulfonylureas, or sulfonamides.
Age-related eligibility rules	Pediatric use is not recommended. Older adults (≥ 65) may use the medicine but require close monitoring.
Condition-specific eligibility rules	Severe renal or hepatic insufficiency are absolute contraindications; use with mild to moderate impairment requires careful patient monitoring.
Pregnancy and lactation eligibility status	Use is contraindicated during both pregnancy and breastfeeding.
Eligibility-related restrictions	Use is contraindicated during treatment with miconazole; insulin therapy is required during severe stress conditions (trauma, surgery, infection).

---

Eligibility Classifications (High-Level)

Category	Classification Details
Eligibility severity classification	Contraindicated: Severe organ failure, Type 1 Diabetes, Pregnancy, Lactation. Not Established: Pediatric patients. Conditional/Caution: Moderate organ impairment, G6PD-deficiency, stress conditions.
Regulatory basis	Summary of Product Characteristics (SmPC) and official Product Monograph/Data Sheets.

---

Resulting Eligibility Structure

Official eligibility statements:

• Use is contraindicated in patients with severe renal or severe hepatic insufficiency.
• The medicine is contraindicated for use during both pregnancy and lactation.
• Glicron is not recommended for the pediatric population because safety and effectiveness have not been established.

Connection to the overall eligibility profile: Regulatory documents strictly define who can and cannot use Glicron by establishing absolute contraindications based on diabetes type, the severity of organ failure, and reproductive status. They also define conditional use for groups like those with mild to moderate organ impairment, while excluding the pediatric population due to unestablished data.

Interactions with other medicines and products

Regulatory documents establish specific interaction patterns for Glicron (Gliclazide) with other medicines, herbal products, and substances, leading to formal constraints on co-administration. These interactions are primarily classified as those that potentiate the glucose-lowering effect (hypoglycaemia risk) or those that modify the drug's systemic exposure (AUC).

Interaction Type	Interacting Substances/Classes	Documented Outcome and Restriction
Contraindicated Combination	Miconazole (systemic or oromucosal gel)	Formal prohibition due to significant potentiation of the hypoglycaemic effect.
Potentiation of Effect	Other Antidiabetic Agents, Beta-blockers, ACE Inhibitors, MAOIs, Phenylbutazone	Additive pharmacodynamic effects increasing the risk of hypoglycemia. Phenylbutazone also increases exposure via protein binding displacement.
Reduction of Efficacy	Glucocorticoids, Danazol, high-dose Chlorpromazine	These agents may cause a diabetogenic effect, resulting in increased blood glucose levels and reduced Gliclazide action.
Pharmacokinetic Modulation	Rifampin (Rifampicin), St. John's Wort	Enzyme inducers that decrease Gliclazide systemic exposure, potentially leading to a loss of blood sugar control.

Alcohol is documented to increase the hypoglycaemic reaction risk by inhibiting the body's compensatory mechanisms, which necessitates caution. Population-specific considerations exist: the risk of a prolonged hypoglycaemic episode from interactions is noted for individuals with Severe Renal or Hepatic Insufficiency. Caution is also advised for co-administration with Fluoroquinolones, particularly in the elderly. When initiating treatment following a long half-life sulfonylurea, regulatory documents suggest a brief treatment-free period may be necessary to avoid an additive effect.

Targeting Pancreatic K-ATP Channels

Glicron initiates its pharmacodynamic action by selectively binding to and inhibiting the ATP-sensitive potassium (K-ATP) channels located on the surface of pancreatic beta-cells. This molecular interaction closes the channels, preventing the efflux of potassium ions and subsequently inducing membrane depolarization of the cell. This depolarization is the essential transition that activates voltage-gated calcium channels.

Initiating the Insulin Secretion Cascade

The resulting influx of calcium ions triggers the internal insulin secretion cascade. This cellular process culminates in the exocytosis (fusion and release) of insulin-containing vesicles into the extracellular space, leading to the release of stored insulin into the bloodstream.

Modulating Systemic Glucose Metabolism

The subsequent increase in circulating insulin facilitates the translocation of glucose transporters to the membranes of peripheral cells (e.g., muscle and adipose tissue). This mechanism increases cellular glucose uptake and utilization, which results in a measurable change in the body's systemic glucose concentration.

How Glicron is Used: Official Administration Guidelines

Glicron (Gliclazide) is an oral medication intended for long-term administration as part of a continuous regimen for Type 2 Diabetes management. Usage is strictly defined by the specific tablet formulation, which includes Standard-Release (IR) tablets (e.g., 40 mg, 80 mg) and Modified-Release (MR) tablets (e.g., 30 mg, 60 mg, 120 mg).

---

Dosing and Frequency

The daily schedule depends entirely on the formulation. Modified-Release tablets are taken as a single dose once daily, while Standard-Release tablets may require divided doses if the daily amount exceeds 160 mg. The maximum daily dose for the MR formulation is 120 mg and for the IR formulation is 320 mg. Dose adjustment, or titration, is typically done cautiously based on blood glucose levels, with increments generally separated by an interval of at least one month.

---

Key Administration Conditions

The medication must be taken with breakfast or the first main meal of the day. This timing is a mandatory condition of use and requires the patient to maintain regular food intake. The tablet must be swallowed whole with water; the MR form should not be crushed or chewed, as this compromises its sustained-action design.

If a dose is forgotten, the instruction is to skip the missed dose and take the next scheduled dose at the usual time; do not double the dose to compensate.

---

Population-Specific Use

Use of Glicron is established for adults only, as efficacy and safety data are not available for the pediatric population. The same dosing regimen is permitted in older adults and in patients with mild to moderate renal impairment, provided the patient is monitored carefully.

Research evidence / Overview of studies for Glicron

Evidence for Glycemic Control in Type 2 Diabetes

The research base related to Gliclazide involves numerous Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies primarily focused on measuring changes in blood sugar control in adults diagnosed with Type 2 Diabetes Mellitus. Researchers used biomarkers, most importantly Glycosylated Hemoglobin (A1c), to track average blood sugar levels over periods ranging from a few weeks up to a year.

Studies reported patterns related to the change in A1c levels observed in the studied adult populations. Comparative research has explored how these changes relate to those seen with placebo or other medications used for glucose control. Some trials described that Gliclazide was evaluated against other oral glucose-lowering agents in studies examining similar changes in these biomarker shifts. These findings describe patterns observed in the studies and contribute to the broader evidence landscape.

---

Evidence for Long-Term Vascular and Organ Health

Research has explored the connection between Gliclazide-based treatment and the risk of long-term health complications related to diabetes, often focusing on outcomes reflecting systemic or functional imbalance. This evidence primarily stems from the large, long-term RCT known as the ADVANCE trial, involving thousands of adults with Type 2 Diabetes who were at high vascular risk.

Researchers in this trial examined a strategy of intensive glucose control (largely using Gliclazide modified release) compared to a standard approach. Findings describe patterns observed in the studies, indicating the intensive control strategy was associated with measurements showing a difference in major microvascular events, including a noted change in the progression of nephropathy. However, the same strategy did not indicate a significant difference in the composite measure of major macrovascular events when compared to the standard approach during the primary follow-up period.

---

What is Still Uncertain About the Research for Glicron

While the research base is extensive, long-term outcomes are not fully established regarding definitive, large-scale comparisons between Gliclazide and newer medications for Type 2 Diabetes for major adverse cardiovascular events as a primary outcome. Comparative evidence is lacking for a direct head-to-head assessment designed to track these specific long-term outcomes with the same rigor as modern cardiovascular outcome trials. Furthermore, research exploring Gliclazide’s use in pediatric or adolescent populations remains insufficient.

Key Studies & References

1. Gliclazide: The composition and form (MedlinePlus Drug Information)

Common questions about Glicron (FAQ)

---

Q: What are the intended health benefits of taking Glicron long-term?

Glicron is prescribed for the long-term management of blood sugar levels in adults with Type 2 Diabetes. Research on the modified-release formulation showed that intensive glucose control was associated with a noted difference in major microvascular events. This included a noted change in the progression of nephropathy (kidney disease).

---

Q: Can Glicron affect liver function or require regular blood tests?

Official information notes that Glicron can, rarely, cause effects on the liver, categorized as Hepatobiliary Disorders. Because of the risk of effects on the blood and liver, official guidelines suggest that individuals with mild to moderate kidney or liver impairment require careful monitoring while taking this medication.

---

Q: What kind of clinical research or evidence supports the use of Glicron?

The medicine's use is supported by numerous Randomized Controlled Trials (RCTs) and Systematic Reviews that track how effective it is. These studies primarily focused on measuring the change in a biomarker called Glycosylated Hemoglobin (A1c) in adults with Type 2 Diabetes.

---

Q: Have studies examined the effects of Glicron on complications like kidney damage?

Yes. The large-scale ADVANCE trial examined long-term vascular health in adults with Type 2 Diabetes. Findings indicated that intensive control was associated with a noted change in the progression of nephropathy, which is a form of kidney damage.

---

Q: What are the potential side effects beyond low blood sugar (hypoglycemia)?

Beyond the most common risk of low blood sugar, the official safety profile lists several potential effects. These include uncommon gastrointestinal disturbances (such as nausea, vomiting, or abdominal pain) and rare effects on the blood and liver function. Transient visual disturbances may also occur when treatment is first initiated.

---

Q: What types of allergic reactions are associated with Glicron?

Official product information states that Glicron is contraindicated if a person has hypersensitivity to Gliclazide, other sulfonylureas, or sulfonamides. Rare dermal side effects, such as a rash, have also been reported with the sulfonylurea class of medications.

---

Q: Can Glicron be used in people who have a history of sulfa allergies?

Official eligibility documents indicate that Glicron is contraindicated (should not be used) in patients with known hypersensitivity to Gliclazide, other sulfonylureas, or sulfonamides. Sulfonamides belong to a group of substances chemically related to sulfa drugs.

---

Q: Is it normal to feel a bit dizzy when first starting Glicron treatment?

Regulatory documents note that Glicron may cause dizziness or drowsiness in some people. This effect may occur due to changes in blood sugar, particularly if levels drop too low.

---

Q: Is it possible to experience digestive side effects such as flatulence or gas?

Uncommon side effects listed in the official safety profile include gastrointestinal disturbances. While specific terms like flatulence or gas are not listed, the category includes symptoms such as abdominal pain, diarrhea, constipation, nausea, and vomiting.

---

Q: Are there other diabetes medications that Glicron is commonly combined with?

Yes, regulatory documents state that Glicron is often combined with Other Antidiabetic Agents, such as insulin, Metformin, or GLP-1 receptor agonists. These combinations require caution and monitoring because they can increase the risk of low blood sugar.

---

Q: What symptoms should be monitored for low blood sugar while taking Glicron?

Since Glicron can cause low blood sugar (hypoglycemia), it is helpful to know common symptoms. These can include headache, dizziness, confusion, weakness, tremor, and rapid heartbeat. Being aware of these signs is important for safe medication use.

---

Q: Are there any long-term health risks associated with Glicron use?

The sulfonylurea class of medications, to which Glicron belongs, carries a regulatory warning regarding a potential increased risk of cardiovascular mortality. However, Gliclazide-specific studies, such as the ADVANCE trial, did not show a significant difference in major macrovascular events.

---

Q: Does Glicron interact with common over-the-counter pain relievers?

Official documents indicate that non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen or aspirin can interact with Glicron. These common pain relievers can increase the glucose-lowering effect of Glicron, which increases the risk of low blood sugar. Paracetamol (acetaminophen) is generally considered safe.

---

Q: Can Glicron be taken at the same time as other prescription medications?

Yes, but caution and monitoring are necessary because Glicron interacts with many classes of prescription medications. Some drugs, such as Beta-blockers, can potentiate its effects, while others, such as Glucocorticoids, can reduce its efficacy.

---

Q: Are there any vitamins or supplements that should not be taken with Glicron?

Regulatory documents indicate that the herbal supplement St. John's Wort is contraindicated because it may decrease the effectiveness of Gliclazide. Caution is generally advised with other herbal remedies and supplements that could also increase the risk of low blood sugar.

---

Q: What is the difference between Glicron and Metformin?

Glicron is classified as a sulfonylurea that works as an insulin secretagogue, meaning it stimulates the pancreas to release stored insulin. Metformin, in contrast, works primarily by reducing the amount of glucose produced by the liver, and it belongs to a different class often prescribed initially.

---

Q: How does Glicron compare to other sulfonylurea drugs?

Glicron is classified as a second-generation sulfonylurea derivative. All drugs in this class share the mechanism of stimulating insulin release. Studies have been conducted to compare the safety profile of Gliclazide, including its cardiac safety, to other drugs within the sulfonylurea class.

---

Q: What are the guidelines regarding driving or operating machinery while on Glicron?

Regulatory guidelines state that if blood sugar levels fall too low, concentration can be affected. Because Glicron may cause dizziness or drowsiness, if these effects occur, driving, operating machinery, or performing dangerous tasks should be avoided.

---

Q: Is Glicron a generic medicine or a brand-name drug?

Glicron is a brand-name preparation whose sole active ingredient is Gliclazide. Gliclazide is the generic name for the pharmaceutical molecule.

---

Q: Can Glicron be taken along with a GLP-1 or SGLT2 inhibitor class of drugs?

Yes, official documents permit Glicron to be taken with other antidiabetic agents, including GLP-1 receptor agonists and SGLT2 inhibitors. As with many combinations, caution and monitoring are necessary because this may increase the blood glucose lowering effect, increasing the risk of low blood sugar.

---

Q: Does Glicron increase the risk of certain heart problems?

The sulfonylurea class as a whole carries a regulatory warning regarding a potential increased risk of cardiovascular mortality. However, the Gliclazide-specific ADVANCE trial did not show a significant difference in major macrovascular events.

---

Q: Does Glicron work by making the body more sensitive to insulin?

The primary mechanism of Glicron is that of an insulin secretagogue, meaning it stimulates the pancreas to release more insulin. Some scientific literature also mentions properties related to increasing the body's sensitivity to insulin as a secondary effect.

---

Q: What is the purpose of regular blood tests while taking Glicron?

Regular blood tests serve two primary purposes: to track the medication's effectiveness by measuring biomarkers like Glycosylated Hemoglobin (A1c), and to monitor for rare side effects. Monitoring is necessary for potential effects on the blood and liver function.

---

Q: What are the typical patient expectations for blood sugar control with Glicron?

Glicron is intended to support blood sugar control toward a lower, more controlled level. Patient expectations for control are measured by tracking patterns related to the change in Glycosylated Hemoglobin (A1c) levels observed in studied adult populations.

---

Q: Are there any known drug-drug interactions with common cold or flu medications?

Yes, caution is needed because some antibiotics and sulfonamides used to treat secondary infections associated with cold or flu can interact with Glicron. These medicines can potentiate the glucose-lowering effect, which increases the risk of low blood sugar.

---

Q: If blood sugar levels stabilize, should a patient continue taking Glicron?

Glicron is intended for continuous long-term administration as part of a diabetes management regimen. Discontinuing the medicine, even if blood sugar levels stabilize, can worsen diabetes control. Discontinuation or changes to the regimen should be discussed with a healthcare professional.

---

Q: What is the role of diet and exercise when taking Glicron?

Glicron is officially indicated for use along with diet and exercise to improve blood sugar control in adults with Type 2 Diabetes Mellitus. Diet and exercise remain essential components of the overall treatment plan.

---

Q: Is Glicron generally effective for all stages of Type 2 diabetes?

Glicron is indicated for Type 2 Diabetes Mellitus when diet and exercise alone are insufficient. However, it is contraindicated (should not be used) in severe metabolic imbalance conditions, such as diabetic keto-acidosis or diabetic pre-coma/coma.

---

Q: Why is Glicron sometimes considered a 'second-line' treatment option?

Official documents state the medicine is used when diet and exercise alone are insufficient to manage blood sugar. Some guidelines indicate that it is typically prescribed if a different initial medicine cannot be taken or is no longer adequately controlling blood sugar.

---

Q: Does Glicron cause an increased sensitivity to sunlight or sunburn?

Photosensitivity reactions, which involve an increased sensitivity to sunlight, have been reported with the sulfonylurea class of medications, to which Glicron belongs.

---

Q: What is the general advice for a sick day when taking Glicron?

Glicron is contraindicated during periods of severe stress, which includes serious infection, trauma, or surgery. During such times, other treatments, like insulin therapy, are often required. This suggests that the continued use of the medication during such times should be urgently reviewed.

Official Storage and Disposal Requirements

Regulatory agencies define specific conditions to maintain the stability and integrity of Glicron (Gliclazide) and ensure responsible disposal.

Storage Conditions

Glicron must be stored at controlled room temperature, specifically below 25 C. Containers and closures must protect the product from foreseeable external factors that could cause contamination or deterioration, preserving its quality, identity, and strength until the expiration date. It is essential to ensure that containers are visually inspected upon handling to prevent the distribution of damaged product.

Disposal and Safety

To prevent accidental exposure, especially by children, unused or expired Glicron should be removed from the home. The preferred method of disposal is utilizing official drug take-back programs (drop-off or mail-back). If these programs are unavailable, disposal may proceed by mixing the medicine with an unappealing substance (like dirt or coffee grounds), sealing it in a plastic bag, and discarding it with household trash. The prescription label must have all personal information permanently scratched out before disposal. Flushing Glicron down the toilet is not generally recommended.